"Survival Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
| Descriptor ID |
D015996
|
| MeSH Number(s) |
E05.318.308.985.550.900 N01.224.935.698.826 N06.850.505.400.975.550.900 N06.850.520.308.985.550.900
|
| Concept/Terms |
Survival Rate- Survival Rate
- Rate, Survival
- Rates, Survival
- Survival Rates
Mean Survival Time- Mean Survival Time
- Mean Survival Times
- Survival Time, Mean
- Survival Times, Mean
- Time, Mean Survival
- Times, Mean Survival
Cumulative Survival Rate- Cumulative Survival Rate
- Cumulative Survival Rates
- Rate, Cumulative Survival
- Rates, Cumulative Survival
- Survival Rate, Cumulative
- Survival Rates, Cumulative
|
Below are MeSH descriptors whose meaning is more general than "Survival Rate".
Below are MeSH descriptors whose meaning is more specific than "Survival Rate".
This graph shows the total number of publications written about "Survival Rate" by people in this website by year, and whether "Survival Rate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 18 | 18 |
| 1997 | 0 | 12 | 12 |
| 1998 | 0 | 23 | 23 |
| 1999 | 0 | 15 | 15 |
| 2000 | 0 | 13 | 13 |
| 2001 | 0 | 24 | 24 |
| 2002 | 0 | 22 | 22 |
| 2003 | 0 | 24 | 24 |
| 2004 | 0 | 29 | 29 |
| 2005 | 0 | 36 | 36 |
| 2006 | 0 | 40 | 40 |
| 2007 | 0 | 41 | 41 |
| 2008 | 0 | 59 | 59 |
| 2009 | 0 | 46 | 46 |
| 2010 | 1 | 56 | 57 |
| 2011 | 0 | 81 | 81 |
| 2012 | 0 | 59 | 59 |
| 2013 | 1 | 71 | 72 |
| 2014 | 2 | 79 | 81 |
| 2015 | 0 | 78 | 78 |
| 2016 | 1 | 90 | 91 |
| 2017 | 1 | 106 | 107 |
| 2018 | 1 | 106 | 107 |
| 2019 | 2 | 100 | 102 |
| 2020 | 0 | 88 | 88 |
| 2021 | 0 | 48 | 48 |
| 2022 | 0 | 15 | 15 |
| 2023 | 0 | 15 | 15 |
| 2024 | 0 | 48 | 48 |
| 2025 | 0 | 37 | 37 |
| 2026 | 0 | 12 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Survival Rate" by people in Profiles.
-
Long-Term Outcomes of Renal Transplant Allografts With De Novo DSA in the Setting of Stable Function. Clin Transplant. 2026 May; 40(5):e70576.
-
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia. Hematol Oncol. 2026 May; 44(3):e70198.
-
Early Liver Transplantation for Alcohol-Associated Hepatitis: A Systematic Review and Meta-Analysis. Clin Transplant. 2026 May; 40(5):e70566.
-
Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431. Pediatr Blood Cancer. 2026 Jun; 73(6):e70293.
-
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes. Leukemia. 2026 May; 40(5):946-954.
-
Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State. Clin Lung Cancer. 2026 May; 27(4):14-23.
-
Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332. Pediatr Blood Cancer. 2026 May; 73(5):e70228.
-
Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors. Pediatr Blood Cancer. 2026 May; 73(5):e70199.
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternational Soft Tissue saRcoma ConsorTium (INSTRuCT). Cancer Med. 2026 Mar; 15(3):e71524.